BIOGEN IDEC (IDP HM) stock market data APIs
€137.16
1.26(0.9%)
as of February 10, 2025
BIOGEN IDEC Financial Data Overview
There is no Profile data available for IDP.HM.
Prev. Close
135.45
Open
137.16
High
137.47
Low
135.82
52 wk Range
133.55-218
Market Cap
30 257 M
Shares Outstanding
0
Revenue
0
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue: 0
- EBITDA: 0
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News
New
Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts.In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healt...
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Analysts on Wall Street project that Biogen Inc. (BIIB) will announce quarterly earnings of $3.45 per share in its forthcoming report, representing an increase of 17% year over year. Revenues are proj...
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook give...
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to Alzhe...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
